Advanced search
Publication Cover
HIV Research & Clinical Practice Volume 21, 2020 - Issue 4
Submit an article Journal homepage
802
Views
6
CrossRef citations to date
0
Altmetric
Article

Identifying appropriate candidates for long-acting antiretroviral therapy: findings from a survey of health care providers in the ATLAS-2M trial

Miranda Murray1 Health Analytics & Outcomes, London, UKView further author information
,
Deanna Kerrigan2 American University, Washington, DC, USAView further author information
,
Krischan J. Hudson3 ViiV Healthcare, Research Triangle Park, NC, USACorrespondence[email protected]
View further author information
,
Nicola Walters4 GSK, London, UKView further author information
,
Tahilin Sanchez Karver5 Johns Hopkins University, Baltimore, MD, USAView further author information
,
Andrea Mantsios2 American University, Washington, DC, USAView further author information
&
Noya Galai5 Johns Hopkins University, Baltimore, MD, USAView further author information
 show all
Pages 105-113 | Received 12 Jun 2020, Accepted 07 Sep 2020, Published online: 13 Oct 2020

References

  • Johnsen AT, Tholstrup D, Petersen MA, Pedersen L, Groenvold M. Health related quality of life in a nationally representative sample of haematological patients. Eur J Haematol. 2009;83(2):139–148.
  • Gogtay JA, Malhotra G. Reformulation of existing antiretroviral drugs. Curr Opin HIV AIDS. 2013;8(6):550–555.
  • Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med. 2000;342(13):921–929.
  • Sullivan AK, Curtis H, Sabin CA, Johnson MA. Newly diagnosed HIV infections: review in UK and Ireland. BMJ. 2005;330(7503):1301–1302.
  • Aldir I, Horta A, Serrado M. Single-tablet regimens in HIV: does it really make a difference? Curr Med Res Opin.. 2013;30(1):89–97.
  • Margolis DA, Gonzalez-Garcia J, Stellbrink HJ, et al. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. Lancet. 2017;390(10101):1499–1510.
  • Swindells S, et al. Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression. N Engl J Med. 2020;382:1112–1123.
  • Orkin C, Arasteh K, Górgolas Hernández-Mora M, et al. Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection. N Engl J Med. 2020;382(12):1124–1135.
  • Murray M, et al. Patient-reported outcomes on long-acting cabotegravir + rilpivirine as maintenance therapy: FLAIR 48-week results. Poster presented at: 10th IAS Conference; July 21–24, 2019; Mexico City, Mexico, MOPEB258.
  • Murray M, et al. Patient views on long-acting HIV treatment: cabotegravir + rilpivirine as maintenance therapy (ATLAS 48-Week Results). Oral Presentation at: 10th IAS Conference; July 21–24, 2019; Mexico City, Mexico, MOAB0103.
  • ATLAS-2M Press Release [cited August 31, 2019]. Available from: https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-reports-positive-phase-iii-study-results-of-investigational-long-acting-injectable-hiv-treatment-regimen-administered-every-two-months/.
  • Overton ET, Richmond GJ, Rizzardini G, et al. Cabotegravir + rilpivirine every 2 months is noninferior to monthly: ATLAS-2M study. Conference on Retroviruses and Opportunistic Infections (CROI); 2020:8–11; Boston, Abstract 34.
  • Mantsios A, Murray M, Sanchez Karver T, Davis W, Margolis D. "I feel empowered": women's perspectives on and experiences with long-acting antiretroviral therapy in the United States and Spain. Infectious Disease Week (IDWeek). Washington, DC; October 2, 2019.
  • Kerrigan D, Mantsios A, Gorgolas M, et al. Experiences with long acting injectable ART: a qualitative study among PLHIV participating in a Phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain. PLoS One. 2018; 13(1):e0190487.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.